Search

The Covid-19 pandemic has highlighted the importance of health technologies to mitigate against the spread of the disease and improve care, dominantly including life-saving vaccines. But the pandemic has also highlighted that the current biopharmaceutical business model, based on the enclosure of these technologies and on the immense accumulation of capital it enables, leads to vast inequalities in healthcare particularly in low and middle-income countries. We believe that the pharmaceutical industry has a moral duty to enable and enact global solidarity through tech sharing instead of tech hoarding, but judging by current technology transfer practices we question their willingness to assume their role in organizing healthcare markets through solidaristic principles. In the absence of a voluntary adoption of solidaristic principles and practices by biopharmaceutical firms, the institutionalization of global solidarity as a fundamental organizing principle for healthcare markets is necessary to strengthen resilience and know-how globally. With this call, we add to existing conceptualizations of solidarity by (a) introducing a global level of solidarity and (b) thinking through the concept not as an abstract humanistic stance but as a concrete organizing principle for global healthcare markets. [ABSTRACT FROM AUTHOR]

This article presents the results of a poll made among the members of the editorial and advisory boards of Valuation Studies. The purpose is to overview the topic that is the remit of the new journal. The poll focused on three questions: 1. Why is the study of valuation topical? 2. What specific issues related to valuation are the most pressing ones to explore? 3. What sites and methods would be interesting for studying valuation? The answers to these questions provided by sixteen board members form the basis of the article. Based on these answers, it identi!es a number of themes concerning the study of valuation, elaborating on the rationale for attending to valuation, the conceptual challenges linked to this, and the specific issues and sites that deserve further attention.

This document presents data from interviews conducted in multiple European countries, including Austria, Belgium, France, Germany, Ireland, Italy, the Netherlands, Switzerland, and the United Kingdom. The interviews involved 80 participants with diverse demographic backgrounds. The purpose of the interviews is not specified in the document. [Extracted from the article]

The controversies surrounding the heavily redacted contracts between the European Commission and Covid-19 vaccine producers have highlighted 'transparency' as a hotly debated concept in the pharmaceutical market. We combine research on transparency with literature on the organization of markets to investigate how such struggles over competing visions of transparency end up shaping markets and their politics. Focusing on the case of the European pharmaceutical market, we demonstrate how market transparency was implemented through devices that enacted specific visions of transparency and produced distinct market organizations over time: transparency for states (until about 1990), transparency for corporations (ca. 1990 to 2010) and transparency for state coalitions (since 2010). We discuss how the specific instrumentations and materializations of such visions of transparency play a crucial role in market politics. This debate also highlights why engaging in controversies over transparency has become increasingly important for those contesting the market status quo – in pharmaceutical markets and beyond. [ABSTRACT FROM AUTHOR]

We explore the role of affect in fuelling and sustaining political organizing in the case of an online type-1 diabetes community. Analysing this community's interactions, we show that the drive towards political transformation is triggered by affective dissonance, but that this dissonance needs to be recurrently enacted through the balanced circulation of objects of pain and hope. We propose the notion of affective resonance to illuminate the dynamic interplay that collectively moderates and fosters this circulation and that keeps bodies invested and reverberating together around shared political goals. Affective resonance points researchers toward the fragile and complex accomplishment that affective politics represents. Focusing particularly on the community's interactions on Twitter, we also reflect on the role of (digital) resonance spaces in how affects circulate. By adopting and transposing concepts from affect theories into the context of patient communities, we further add important insights into the unique embodied challenges that patients with chronic illness face. Highlighting the hope induced by techno-bodily emancipation that intertwine into a particular form of political organizing in such healthcare movements, we give emphasis to patient communities' deeply embodied affects as important engines for political, social and economic change. [ABSTRACT FROM AUTHOR]

Prior work on performativity has illustrated how theories intervene in economic organizing. We expand this body of research by studying how concepts, and particularly those that are loosely defined and/or not widely understood, provoke their own realities through experiments. We examine how different experimental set-ups allow these concepts to be seized by a multitude of actors all wishing to instantiate worlds in their own interests, and how they potentially open up multiple competing realities as a result. We follow the concept of mobility-as-a-service as it mobilizes various experiments across public and private realms in Stockholm and Dublin, and we analyse how specific types of experiment co-produce epistemic and ontological work. Our results illustrate how different experimental designs can be conducive in taming and/or framing ambiguous concepts through interconnected processes of such onto-epistemological work. This highlights the distributed and relational and also the 'provocative' facets of performing ambiguous concepts through experiments. We discuss the consequences of these insights for how we think about scaling from experiments to broader socio-economic realities. [ABSTRACT FROM AUTHOR]

This paper investigates how early venture entrepreneurs engage in socially embedded practices to resource their firm. We contribute to an emerging literature that calls for a shift in perspective from [...]

Prices for new medications have strongly increased over the last decades, reaching levels that could endanger healthcare insurance systems. Focusing on the French case, this article builds on the structural approach of business power and investigates how this situation results from the construction of market boundaries that created unassailable spaces for high pricing. Starting from the 1990s, it traces how high drug prices relied on the construction of a market setting first designed to increase pharmaceutical prices, in which the negotiating position of the state was deliberately weakened. But the politics of maintaining such high drug pricing quickly required reshaping the boundaries of the pharmaceutical market and concentrating the favourable negotiation framework on a small number of innovative medicines. Most recently, the spiralling of prices for these medicines have necessitated yet another revisiting of these market boundaries. High drug prices do not result from direct business power by the pharmaceutical sector; rather, the pharmaceutical sector depends on boundary-work performed in cooperation with state institutions to carve out domains for favourable market pricing. Emphasising the politics of this boundary-work thus ultimately also signals its potential reversibility. [ABSTRACT FROM AUTHOR]

This article, written by two members of the advocacy organisation Access to Medicines Ireland, analyses current discourses and practices around global COVID-19 vaccine distribution. As vast imbalances in vaccination coverage continue to characterise global vaccine distribution, we argue that some of the public discourses and distribution mechanisms are coloured by a colonial legacy, which substitutes local capacity building in low and middle-income countries with donations, and substitutes a transparent public debate around how to tackle these inequalities with a discourse that explains them away through perpetuating such tropes as 'vaccine hesitancy' or 'wastage'. Even though such claims have been continually refuted by scientific evidence, the pharmaceutical industry and many high-income country governments keep reiterating them. By dismantling such myths, we point to the legacies from which they have emerged. Flagging the possibility of alternative discourses and practices in global health, we trace the recent history of the access to medicines movement. We argue for a need to suspend intellectual property rights rules around COVID-19 health technologies through the so-called Trade-Related Aspects of Intellectual Property Rights (TRIPS) waiver, citing positive exemplars of vaccines developed through an open science paradigm as a counterpoint to the pharmaceutical industry's claims that such a waiver would have chilling effects on the global pharmaceutical innovation system. We close by highlighting development education opportunities around global access to medicines and universal healthcare. [ABSTRACT FROM AUTHOR]

An introduction is presented in which the editor discusses articles in the issue on topics including the policies around COVID technologies, techno-solutionism exacerbating existing social inequalities and mistrust in governments and digital contact tracing as a case for how public health and policy approaches governing the pandemic across the globe.

Recent debates in public health and social sciences have shown how biofinancialization has been fuelled by patents' transformation into 'patent-as-assets'. This paper traces the historical construction of one such patent-as-asset bundle: the multi-billion worth architecture of patents behind the hepatitis C blockbuster drug sofosbuvir. Following this process from the late 1980s to present times, we highlight the ontological entanglements of pharmaceutical patents and the scientific, legal, commercial and political contestations that result from the focal firms' assetization projects. By shining a light on these entanglements, our paper points to the extraordinary historical conditions required for the assetization of drug patents as well as to their vulnerability to contestations. In particular, we highlight new forms of patent activism that threaten the 'asset condition' of high-priced pharmaceuticals. [ABSTRACT FROM AUTHOR]

We bring together recent discussions on data capitalism and biocapitalization by studying value flows in consumer genomics firms—an industry at the intersection between health care and technology realms. Consumer genomics companies market genomic testing services to consumers as a source of fun, altruism, belonging and knowledge. But by maintaining a multisided or platform business model, these firms also engage in digital capitalism, creating financial profit from data brokerage. This is a precarious balance to strike: If these companies' business models consist of assetizing the pool of genomic data that they assemble, then part of their work has to revolve around obscuring to consumers any uncertainties that would potentially impinge on these processes of assemblage. We reflect on the nature of these practices and the market relationships that enable them, and we relate this reflection to debates around alternative market arrangements that would potentially mitigate the extractive tendencies of these and other digital health firms. [ABSTRACT FROM AUTHOR]

We live in an era where models of governing are changing rapidly under multifaceted evolutionary pressures and where, at the same time, organizational fields are becoming increasingly networked. With this paper, we add to the field dynamics literature, focusing on the space where these evolutionary pressures coincide – the interactions of Governments and interorganizational networks. We examine the roles that interorganizational networks play in relation to Government actors under particular long- and short-term institutional and governance conditions. We articulate four roles that networks may play in relation to Government: advocate, technology, judge and ruler. We argue that long-term institutional logics, combined with short-term Government action in response to a particular field evolution, may predict the role that the interorganizational network will assume in relation to Government in that particular field scenario. We discuss flows through the typology as conditions change and we conclude by presenting an agenda for future research in the field dynamics and interorganizational networks research domains that leverages our proposed network role typology. [ABSTRACT FROM AUTHOR]

This paper reflects on the relationship between high-tech disruption narratives and uncertainty. My main argument is that an economic sociology of the future is incomplete without addressing the 'demonic' or rather eschatological elements apparent in the promissory twin rhetoric of disruption and inevitability that a number of contemporary technology firms employ. The conjuring up of liberatory high-tech futures implicates a political-philosophical perspective of the end game. It utilizes at once the productive power of uncertainty to create visions of 'absolute riches' and societal gain but at the same time narrows these futures down to one inevitable alternative to the status quo. Through the examples of two Silicon Valley disruptor firms, I argue that these eschatological narratives need to be opened to social scientific critique in order to examine their potential societal consequences above and beyond the narrow geographic confines of 'the Valley.' [ABSTRACT FROM AUTHOR]

Over the last decade, a steady stream of academic research and practitioner articles has examined the adoption and use of information technology (IT) applications in sales and customer services. In much of this literature, sales-related IT tools have been heralded as enhancing salespeople's customer service delivery, professionalism and general sales effectiveness. However, the literature has yet to investigate the precise nature of salespeople's experience with IT tools in their daily sales tasks. Specifically, a core area of salespeople's skills -- namely their ability to practice relationship selling -- has been ignored by the sales management literature examining the impact of such tools. This research investigates how the incorporation of IT tools in salespeople's customer interactions affects salespeople's perceived relational competencies. Results indicate that while IT tools can enhance some relational competencies, they are likely to inhibit other competencies that may be crucial in industries where close personal customer relationships are core to a firm's success. [ABSTRACT FROM AUTHOR]

How do actors innovate markets in cases of perceived market failures? This paper’s aim is to examine what happens when a market is innovated or, as we call it, ‘redevised’ in situations where public and commercial interests significantly diverge. Market devices can serve an important function in such attempts to innovate markets: they are material and/or social arrangements that are put into place to shape the market in question in certain ways. But can such devices really transform a market from within? To examine this question we trace the history of the Geneva Medicines Patent Pool, a civil society initiative introduced to change pharmaceutical firms’ licensing and collaboration practices in the market for HIV/AIDS medicines. Our empirical results indicate that redevising a market in response to market failures can shift the market’s frames and contribute to altering its practices, but that this is a pragmatic and often lengthy process that is never fully predictable in advance. By attending to the intended and unintended consequences - or misfires - of redevising a market, our study raises important questions around acting in and on the market, market innovation’s’ ontological impact, zooming in and zooming out when studying redevising, and attending to the temporality of market innovation. [ABSTRACT FROM AUTHOR]

This article draws from two conceptual lenses – the sociology of expectations and market studies – to investigate the relationship between technology hype and market investments: which promises and expectations surround hype and how they come together to shape actors’ investments in an emerging market. We address this question through analysing a contemporary hype in a technology marketing context: digital healthcare. Our aim is to trace how market actors create, support and evaluate a market hype; how hype and market investments are related; and whether hype contributes to irreversibilities in shaping emerging market forms and categories. Our study indicates that hypes contribute tangibly to producing the market, not least by channelling financial, symbolic and material market investments. Furthermore, by highlighting how socio-economic, technological and policy promises become affectively loaded through circulation, we add a novel dimension to existing insights into the socio-cognitive construction of markets. We caution technology marketers, policymakers and investors against blindly following technology hype, especially when it encourages companies to engage in market investment that is unhinged from broader systems and societal, ethical or economic concerns. [ABSTRACT FROM AUTHOR]

The purpose of our article is to propose that compromising is a constitutive characteristic of those marketing systems that entail matters of public interest or concern. In such markets, actors design compromises as they encounter criticisms of and contending justifications for the market’s products, as these refer to price, efficiency in production and use, regulatory compliance or ecological sustainability. Tests and justifications are vital in order to determine what is valuable and by which measure. As a theory framework, the economic sociology of conventions provides a basis for assessing these contests, compromises, and justifications over the issue of worth in a marketing context. Through an ethnographic study of the regulated activities of chemicals service companies supporting the upstream petroleum industry, we assess how actors evaluate and justify the market’s products and services in this environmentally sensitive setting by means of tests drawing from different orders of worth: the green, the industrial and the market order. Our contributions show that by artful and pragmatic compromising around exchanges, actors in marketing systems can balance several conflicting orders of worth over the question of worth without needing to converge on an overriding institutional logic. [ABSTRACT FROM AUTHOR]